LIFE-THREATENING CONDITIONS IN CHILDREN AND ADOLESCENTS WITH CARDIOINHIBITOR SYNCOPE DURING VENIPUNCTURE
Abstract
To analyze potential riskfactors and markers of life-threatening conditions in children with recurrent neurocardiogenic syncope developed at the background of medical procedures, 87 patients aged 2 17 years with syncope occurred predominantly at the background of venipuncture were examined.
About the Authors
E. B. Polyakova
Московский научно-исследовательский институт педиатрии и детской хирургии Росмедтехнологий, Федеральный детский центр диагностики и лечения аритмий
Russian Federation
Russian Federation
M. A. Shkolnikova
Московский научно-исследовательский институт педиатрии и детской хирургии Росмедтехнологий, Федеральный детский центр диагностики и лечения аритмий
Russian Federation
Russian Federation
V. V. Bereznitskaya
Московский научно-исследовательский институт педиатрии и детской хирургии Росмедтехнологий, Федеральный детский центр диагностики и лечения аритмий
Russian Federation
Russian Federation
E. N. Bortsova
Московский научно-исследовательский институт педиатрии и детской хирургии Росмедтехнологий, Федеральный детский центр диагностики и лечения аритмий
Russian Federation
Russian Federation
References
1. Brignole M., Alboni P., Benditt D. et al. Task Force on syncope: Guidelines on management (diagnosis and treatment) on syncope. Eur. Heart J 2001; 22: 1256-1306.
2. Moya A., Brignole M., Menozzi C., Garcia-Civera R., Tognarini S., Mont L., Botto G., Giada F., Cornacchia D. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation 2001; 104:1261-1267.
3. Brignole M., Alboni P. Benditt D. et al. Task Force on syncope: Guidelines on management (diagnosis and treatment) of Syncope-Update 2004. Eur. Heart J 2004; 25: 2054-2072.
4. Linzer M., Yang E.H., Estes N.A. et al. Diagnosing syncope. Pt.1 Ann. Intern. Med. 1997; 126 (12): 989-996.
5. Linzer M., Yang E.H., Estes N.A. et al. Diagnosing syncope. Pt.2. Ann. Intern. Med. 1997; 127 (1): 76-86.
6. Strieper M.J., Campbell R.M.J. Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope. Am Coll Cardiol 1993; 22: 594-597.
7. Disertori M., Brignole M., Menozzi C., et al. Management of patients with syncope referred urgently to general hospitals. Europace 2003; 5: 283-291.
8. Ammirati F., Colivicchi F., Minardi G., et al. Hospital management of syncope: the OESIL study G Ital Cardiol 1999; 29: 533-539.
9. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. A report of the American College of Cardiology/Ameri can Heart Association Task Force on practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation. 2008; 117:2820-2840.
10. Connolly S.J., Sheldon R., Thorpe K.E. et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: second vasovagal pacemaker study (VPS II): a randomized trial. JAMA. 2003; 289(17):2224-2229.
11. Wagshal A.B., Weinstein J. M., Weinstein O., Zeldetz V., Damri E., Ilia R., Katz A. Do the recently modified pacemaker guidelines for neurocardiogenic syncope also apply to young patients? Cardiology. 2004;102:200-205.
12. Ermis C., Benditt D. G. Recurrent falls: pace now or wait for another fall? Heart. 2009; 95(5):350-352.
13. Agras S., Sylvester D., Oliveau D. The epidemiology of common fears and phobia. Compr Psychiatry. 1969;10:151-156.
14. Costello C.G. Fears and phobias in women: a community study. J Abnorm Psychol. 1982;91:280 -286.
15. American Psychiatric Association. Specific phobia (formerly simple phobia). In: Diagnostic and statistical manual for mental disorders-fourth edition: DSM-IV. Washington, DC: American psychiatric association; 1994; 405-411.
16. Marks I. Blood-injury phobia: a review. Am J Psychiatry. 1988;145: 1207-1213.
17. Thyer B.A., Himle J., Curtis G.C. Blood-injury-illness phobia: a review. J Clin Psychol. 1985;41:451-459.
18. Ogata H., Iinuma N., Nagashima K., et al. Vasovagal reactions in blood donors. Transfusion. 1980; 20:679-683.
19. Sutton R., Petersen M., Brignole M., Raviele A., Menozzi C., Giani P. Proposed classification for tilt induced vasovagal syncope. Eur J Cardiac Pacing Electrophysiol 1992; 3:180-183.
20. Полякова Е.Б. Прогностическое значение синусовой брадикардии при различных вариантах течения синдрома слабости синусового узла у детей. Автореф. дис. канд. мед наук М, 2007, 24.
21. Макаров Л.М. Холтеровское мониторирование. Медпрактика-М М, 2003; 340.
22. Школьникова М.А. Жизнеугрожающие аритмии у детей. М 1999; 230.
23. Rodgers S.F. Safety of intravenous sedation administered by the operating oral surgeon: the first 7 years of office practice. J Oral Maxillofac Surg 2005;63:1478-83.
24. Wakita R., Ohno Y., Yamazaki S., Kohase H., Umino M. Vasovagal syncope with asystole associated with intravenous аcess. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:e28-e32.
25. Accurso V., Winnicki N., Shamsuzzaman Abu S.M., Wenzel A., Johnson A.K., Somers V.K. Predisposition to vasovagal syncope in subjects with blood/injury phobia. Circulation 2001; 104:903-907.
26. Van Lieshout J.J., Wieling W., Karemaker J.M., Ackberg D.L. The vasovagal responses. Clin Sci 1991; 81:575-586.
27. Kosinski D., Grubb B.P., Temesy-Armos P. Pathophys iological aspects of neurocardiogenic syncope: current concepts and new perspective. PACE 1995;18:716-724.
28. Mosqueda-Garcia R., Furlan R., Fernandez-Violante R. et al. Sympathetic and baroreceptor reflex function in neurally mediated syncope evoked by tilt. J. Clin. Invest. 1997;99:2736 -2744.
29. Thomson H.L., Wright K., Frenneaux M. Baroreflex sensitivity in patients with vasovagal syncope. Circulation 1997;95:395- 400.
30. Abboud F.M. Neurocardiogenic syncope. N. Engl. J. Med. 1993;328:1117-1120.
31. Riegger G.A., Wagner A. Excessive secretion of vasopressin during vasovagal reaction. Am. Heart J. 1991; 121: 602-603.
32. Betsuyaku T., Kumamoto H., Yokosiki N., Nomura T., Yosida I., Sakurai M., Kitabatake A. A case of vasovagal syncope associated with venipuncture. Kokyu To Junkan. 1992; 40(8):831-3.
33. Pierre B., Fauchier L., Breard G., Marie O., Poret Ph., Babuty D. Implantable loop recorder for recurrent syncope: influence of cardiac conduction abnormalities showing up on resting electrocardiogram and of underlying cardiac disease on follow-up developments. Europace. 2008; doi:10.1093/europace/eun039.
34. Полякова Е.Б., Школьникова М.А., Березницкая В.В., Борцова Е.Н Пароксизмальные критические нарушения функции синусового узла как причина повторных синкопальных состояний у детей. // Мат. V Всеросс. Конгресса «Детская кардиология 2008», г. Москва, 6-7 июня 2008 г. - с.277-278.
35. Sheldon R., Morillo C., Kralm A. Management of vasovagal syncope. Expert Rev Cardiovas Ther, 2004;2:915-923.
36. Raviele A., Giada F., Menozzi C., et al. A randomized, double blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNAPCE). Eur Heart J, 2004;25:1741-1748.
37. Sud S., Massel D., Klein G. J., Leong-Sit P., Yee R., Skanes A.C., Gula L.J., Krahn A.D. The Expectation Effect and Cardiac Pacing for Refractory Vasovagal Syncope. The American Journal of Medicine, 2007;120,1:54-62.
38. Brignole1 M., Sutton R., Menozzi C., Garcia-Civera R., Moya A., Wieling W., Andresen D., Benditt D.G., Vardas P. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J, 2006; 27:1085-1092.
39. Van Dijk N., Velzeboer S.C.J.M., Destree-Vonk A., Linzer M., Wieling W. Psychological treatment of malignant vasovagal syncope due to bloodphobia. PACE 2001; 24:122-124.
40. Cho E.J., Rho T.H., Kim H.Y., Kim C. J., Lee M.Y., Jin S.W., Park J.C., Kim J.H., Hong S.J., Choi K.B. Recurrent asystoles associated with vasovagal reaction during venipuncture. The Korean journal of internal medicine 2000; 15(3):232-5.
41. Morillo C.A., Leitch J.W., Yee R., Klein G.J. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J. Am. Coll. Cardiol. 1993;22:1843-1848.
42. Raviele A., Brignole M., Sutton R. et al. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double blind, randomized, placebo-controlled trial. The Vasovagal Syncope International Study. Circulation 1999;99:1452-1457.
43. Мadrid A., Ortega I., Robollo G.J. et al. Lack of efficacy of atenolol for the prevention of neurally-mediated syncope in highly symptomatic population: a prospective double-blind, randomized and placebo-controlled study. J. Am. Coll. Cardiol. 2001;37:554-557.
44. Ward C.R., Gray J.C., Gilroy J.J. et al. Midodrine a role in the management of neurocardiogenic syncope. Heart 1998;79:45-49.
45. Perez-Lugones A., Schweikert R., Pavia S. et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc. Electrophysiol. 2001;12:935-938.
46. Fitzpatrick A.P., Ahmed R., Williams S., Sutton R. A randomized trial of medical therapy in «malignant vasovagal syndrome» or «neurally-mediated bradycardia/hypotension syndrome». Eur. J. Cardiac. Pacing Electrophysiol 1991;1:99-102.
47. Lee T.M., Su S.F., Chen M.F. et al. Usefullness of transdermal scopolamine for vasovagal syncope. Am. J. Cardiol. 1996;78:480-482.
48. Takata T.S., Wasmund S.L., Smith M.L. et al. Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. Circulation 2002;106:1500-1504.
49. Meyer K., Galler A., Lietz R., Siekmeyer W. Neuro-cardiogenic syncope in 10-year-old boy. Pediatr Cardiol 2001;22:415-416.
50. Brignole M. International study on syncope of uncer tain aetiology 3 (ISSUE 3): pacemaker therapy for patients with asystolic neurally-mediated syncope: rationale and study design. Europace. 2007; 9(1):25-30.
51. Engel G.L. Psychologic stress. Vasodepressor (vasovagal) syncope, and sudden death. Ann Intern Med 1978;89:403-12.
52. Schrader P.L., Pontzer R., Engel T.R. A case of being scared to death. Arch Intern Med 1983;143:1793-4.
53. McIntosh H.D. The stabilizing and unstabilizing influences of neurogenic and vascular activities of the heart as related to sudden cardiac death. J Am Coll Cardiol 1985;5:105-10.
54. Maloney J.D., Jaeger F.J., Fouad-Tarazi F.M., Morris H.H. Malignant vasovagal syncope; prolonged asystole provoked by head-up-tilt. Cleve Clin J Med 1988;55:542-8.
55. Milstein S., Buetikofer J., Lesser J., Goldenberg I.F., Benditt D.G., Gornick C. et al. Cardiac asystole: a manifestation of neurally mediated hypotension-bradycardia. J Am Coll Cardiol 1989;14:1626-32.
56. McLeon K., Wilson N., Hewitt J., Stephenson J. Double-blind trial of cardiac pacing for severe childhood neurally mediated syncope with reflex anoxic seizures. Pacing Clin Electrophysiol 1999; 22:807.
57. Kelly A.M., Porter J., McGoon M.D., Espinosa R.E., Osborn M.J., Hayes D.L. Breath-Holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics 2001; 108:3:698-702.
58. Benditt D.G. Which syncope patients should be evaluated and treated in hospital, and which can be managed as outpatients? In. The evaluation and treatment of syncope. (eds. Blanc J.J., Brignole M., Sutton R.) Elmsford, NY, Futura/Blackwell Publishing, 2003; 51-54.
Review
For citations:
Polyakova E.B., Shkolnikova M.A., Bereznitskaya V.V., Bortsova E.N. LIFE-THREATENING CONDITIONS IN CHILDREN AND ADOLESCENTS WITH CARDIOINHIBITOR SYNCOPE DURING VENIPUNCTURE. Journal of Arrhythmology. 2009;(56):5-13. (In Russ.)
Views:
186
Email this article 